摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-碘喹啉-4-醇 | 64965-48-6

中文名称
3-碘喹啉-4-醇
中文别名
3-碘-4-羟基喹啉;4-羟基-3-碘喹啉
英文名称
3-iodoquinolin-4(1H)-one
英文别名
3-Iodoquinolin-4-OL;3-iodo-1H-quinolin-4-one
3-碘喹啉-4-醇化学式
CAS
64965-48-6
化学式
C9H6INO
mdl
——
分子量
271.057
InChiKey
HZBSJOAFGNZACW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933499090
  • WGK Germany:
    3
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    室温和干燥环境

SDS

SDS:20349054e0d2e7b231bf94702ef53d84
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Iodoquinolin-4-Ol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 271,06 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-Iodoquinolin-4-Ol
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-Iodoquinolin-4-Ol
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

用途

4-羟基-3-碘喹啉可用作医药合成中的中间体。该化合物可通过将4-羟基喹啉作为反应原料,与碘或碘的碘化钾溶液进行反应来制备。

反应信息

  • 作为反应物:
    描述:
    3-碘喹啉-4-醇 、 sodium hydride 、 potassium carbonateN,N'-二甲基乙二胺 作用下, 以 四氢呋喃甲苯 、 mineral oil 为溶剂, 反应 50.0h, 生成 4-甲基-N-(1-甲基-4-氧代-1,4-二氢喹啉-3-基)苯磺酰胺
    参考文献:
    名称:
    3-卤代-4(1 H)-喹诺酮与各种含氮亲核试剂的一般铜粉催化乌尔曼型反应
    摘要:
    使用铜催化的Ullmann C–N键形成策略以中等至定量的产率合成了3-(N-取代的)4(1 H)-喹啉酮。从3-卤代-4(1 H)-喹诺酮类化合物开始,已成功使用了各种亲核试剂,包括酰胺,内酰胺,磺酰胺和含NH的唑。在所有情况下,反应都在甲苯中迅速进行,并通过使用铜粉作为催化剂,DMEDA作为配体和K 2 CO 3作为碱进行。此外,在我们的Cu / DMEDA催化剂体系下,其他相关杂环,例如3-溴喹啉-2(1 H)-ones,3-溴香豆素和3,5-二溴-2-吡啶酮显示出与各种亲核试剂的良好或非常高的反应性。 。
    DOI:
    10.1021/jo200680j
  • 作为产物:
    参考文献:
    名称:
    The Preparation of 3-Halo-4-dialkylaminoalkylaminoquinoline Derivatives
    摘要:
    DOI:
    10.1021/ja01216a044
点击查看最新优质反应信息

文献信息

  • [EN] AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS<br/>[FR] (THIO)AMIDES AZABICYCLIQUES EN TANT QUE COMPOSÉS FONGICIDES
    申请人:BAYER AG
    公开号:WO2021233861A1
    公开(公告)日:2021-11-25
    The present invention relates to azabicyclic (thio)amide compounds and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these compounds
    本发明涉及吡啶环(硫)酰胺化合物及其用途,用于控制植物病原微生物,如植物病原真菌。它还涉及制备这些化合物的过程和中间体。
  • A simple method for iodination of heterocyclic compounds using HIO4/NaCl/silica gel/H2SO4 in water
    作者:Abolfazl Hosseini、Mohammad A. Khalilzadeh、Masoumeh Hosseinzadeh、Mahmoud Tajbakhsh
    DOI:10.1007/s00706-011-0611-6
    日期:2012.4
    AbstractA fast and simple method for iodination of some heterocycles is reported. The reactions were carried out in water, using HIO4/H2SO4/NaCl/silica gel at moderate temperatures of 25–50 °C. Graphical Abstract
    摘要报道了一种快速简单的碘化某些杂环的方法。反应在25–50°C的中等温度下使用HIO 4 / H 2 SO 4 / NaCl /硅胶在水中进行。 图形概要
  • Evaluation of 1,2,3‐Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX‐770 and VX‐809
    作者:Jake E. Doiron、Christina A. Le、Britton K. Ody、Jonathon B. Brace、Savannah J. Post、Nathan L. Thacker、Harrison M. Hill、Gary W. Breton、Matthew J. Mulder、Sichen Chang、Thomas M. Bridges、Liping Tang、Wei Wang、Steven M. Rowe、Stephen G. Aller、Mark Turlington
    DOI:10.1002/chem.201805919
    日期:2019.3.7
    assay could be due to the inability of VX‐770 triazole derivatives to reach the CFTR binding site. Moreover, in addition to the negative impact on biological activity, triazoles in both structural classes displayed decreased metabolic stability in human microsomes relative to the analogous amides. In contrast to the many studies that demonstrate the advantages of using the 1,2,3‐triazole, these findings
    1,2,3-三唑已成功用作多种治疗环境中的酰胺生物等排体。基于这一先例,合成了源自 VX-809 和 VX-770 的三唑类似物,它们是囊性纤维化跨膜电导调节剂 (CFTR) 的主要含酰胺调节剂,并评估了 CFTR 调节作用。与 VX-809 相比,源自 VX-809 的三唑11在细胞 TECC 测定中的 F508del-CFTR 校正中表现出显着降低的功效。令人惊讶的是,源自增效剂 VX-770 的三唑类似物在细胞 Ussing 室测定中没有显示出对 F508del、G551D 或 WT-CFTR 的增强作用。然而,膜片钳分析显示,三唑60与 VX-770 类似,可增强 WT-CFTR。60在无细胞膜片钳实验中的功效表明,细胞测定中活性的丧失可能是由于 VX-770 三唑衍生物无法到达 CFTR 结合位点。此外,除了对生物活性的负面影响之外,与类似的酰胺相比,两种结构类别的三唑在人体微粒
  • Expeditious synthesis of pyrano[2,3,4-de]quinolines via Rh(<scp>iii</scp>)-catalyzed cascade C–H activation/annulation/lactonization of quinolin-4-ol with alkynes
    作者:Gang Liao、Hong Song、Xue-Song Yin、Bing-Feng Shi
    DOI:10.1039/c7cc04113f
    日期:——

    One-step synthesis of tetracyclic pyrano[2,3,4-de]quinolones via Rh(iii)-catalyzed cascade C–H activation/annulation/lactonization is described.

    通过Rh(III)-催化的级联C-H活化/环化/内酯化一步合成四环吡喃并[2,3,4-de]喹啉酮。
  • [EN] TOLL-LIKE RECEPTOR 8 AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS TOLL-LIKE 8
    申请人:UNIV KANSAS
    公开号:WO2015095780A1
    公开(公告)日:2015-06-25
    Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.
    本文描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂,例如TLR8激动剂。这些化合物可以包含在药物组合物中,并用于治疗需要TLR8激动剂的情况。药物组合物可以包括任何成分,例如载体、稀释剂、赋形剂、填料或其他在药物组合物中常见的成分。这些化合物可以是本文所述的化合物,以及其衍生物、前药、盐、立体异构体,或在任何手性中心具有任何手性,或互变异构体、多晶形态、溶剂合剂,或其组合。因此,这些化合物可以用作疫苗的辅助剂,以及用于本文描述的其他治疗目的。这些化合物可以具有本文描述的任何一个化学式或其衍生物。
查看更多